AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE III STUDY OF SECOND-LINE CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER PATIENTS WHO HAVE RECEIVED FIRST-LINE CHEMOTHERAPY PLUS BEVACIZUMAB

ABSTRACT: Primary objectives: To compare the progression-free-survival of second-line chemotherapy with Bevacizumab to second-line chemotherapy alone in patients treated with first-line chemotherapy + Bevacizumab. Primary endpoints: progression-free-survival

DISEASE(S): Metastatic Colorectal Cancer Patients,Colorectal Cancer Metastatic

PROVIDER: 2542918 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR